Core Insights - Chautauqua Capital Management's fourth-quarter 2025 investor letter highlights a strong performance in global equities, with international markets outperforming U.S. equities significantly, aided by a weaker dollar and improving trade conditions [1] - The Baird Chautauqua International Growth Fund returned +0.11% in Q4 2025, lagging behind the MSCI ACWI ex-U.S. Index's +5.05%, while the Global Growth Fund gained +4.18%, outperforming its MSCI ACWI Index® ND's +3.29% [1] - The fund remains focused on high-quality businesses with strong cash flows and balance sheets, despite near-term headwinds from sector rotations and profit-taking in Greater China [1] Company-Specific Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is highlighted as a biotechnology leader with a focus on innovative medicines for serious diseases, reporting a one-month return of approximately -0.30% and shares remaining about 12.42% above their 52-week high [2] - As of January 26, 2026, Regeneron's stock closed at approximately $762.65 per share, with a market capitalization of about $81.779 billion [2] - Regeneron reported strong Q3 2025 results, with top- and bottom-line beats driven by Dupixent and Eylea HD, and expects resolution of manufacturing issues in 2026 along with important pipeline data readouts [3] - Regeneron is not among the 30 Most Popular Stocks Among Hedge Funds, with 78 hedge fund portfolios holding the stock at the end of Q3, an increase from 73 in the previous quarter [3]

Netflix Inc. (NASDAQ:NFLX) is one of the best US stocks to buy and hold in 2026. On January 21, Needham lowered the price target on Netflix to $120 from $150 but maintained a Buy rating. Following Q4 2025 results, the firm noted that the company’s 2026 guidance is distracted by $275 million in projected legal and regulatory expenses, which are expected to dampen margins and free cash flow. Still, Needham recommends buying on weakness due to a robust 2026 content lineup and improved retention among its 325 ...

SM Energy Company (NYSE:SM) is one of the 10 Cheap Stocks with Huge Upside Potential. Tim Rezvan of KeyBanc reaffirmed his Buy rating on SM Energy Company (NYSE:SM) stock, along with the price target of $28, on January 17. Earlier in the same week, on January 13, RBC Capital analyst Scott Hanold lowered his price target on the stock from $35 to $29. However, the analyst kept his Hold rating on the shares. The analyst explained in a research note that the firm updated its estimates after completing its fina ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Cheap Stocks with Huge Upside Potential. On January 20, Canaccord Genuity raised BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) price target from $84 to $98, implying 74.4% upside from the current share price. On January 13, Wedbush analyst Yun Zhong reaffirmed his Buy rating on the stock while maintaining a price target of $94. Yun Zhong’s Buy rating is based on several factors that reinforce the company’s ability to deliver sustained long-term gro ...

Core Viewpoint - Johnson & Johnson (NYSE: JNJ) is recognized as a strong investment opportunity, particularly highlighted by Guggenheim's positive outlook following solid Q4 results and favorable 2026 guidance [2][4]. Financial Performance - Guggenheim analyst Vamil Divan raised the price target for Johnson & Johnson to $240 from $227, maintaining a Buy rating after the company reported solid fourth-quarter results [2]. - The company’s fourth-quarter earnings for 2025 were released on January 21, accompanied by a 2026 outlook that exceeded Wall Street expectations [4]. - Johnson & Johnson forecasts 2026 sales between $99.5 billion and $100.5 billion, surpassing analyst expectations of approximately $98.9 billion [5]. Adjustments and Forecasts - Following the quarter, Divan adjusted his model, increasing near-term forecasts for Tremfya and raising estimates for several newer products, while also factoring in faster erosion for Stelara [3]. - Despite challenges such as a drug pricing agreement with the Trump administration and approximately $500 million in tariff-related costs, the company’s guidance remained robust [4][5]. Business Segments - Johnson & Johnson operates in the healthcare sector through its Innovative Medicine and MedTech segments, which include drug development and medical devices [6].

Core Viewpoint - Johnson & Johnson (NYSE: JNJ) has provided a strong 2026 outlook, surpassing Wall Street expectations despite facing significant challenges, including a drug pricing agreement and tariff-related costs [2][3]. Financial Performance - For 2026, Johnson & Johnson anticipates sales between $99.5 billion and $100.5 billion, exceeding analyst projections of approximately $98.9 billion [3]. - The company expects full-year earnings per share to be in the range of $11.43 to $11.63, slightly above the consensus estimate of $11.45 [3]. Management Outlook - CEO Joaquin Duato expressed optimism during the earnings call, indicating that the company expects to achieve faster growth in 2026 compared to 2025 and aims for double-digit growth by the end of the decade [4]. Business Operations - Johnson & Johnson operates across the healthcare sector, developing and selling a diverse range of products, including pharmaceuticals and medical devices [4]. Challenges - The drug pricing agreement with the Trump administration is projected to cost the company "hundreds of millions of dollars," alongside an expected $500 million in tariff-related costs impacting its medical devices segment [2][3].

We recently published 10 Big Names Stumbling Hard. Revolution Medicines Inc. (NASDAQ:RVMD) was one of the worst performers on Monday. Revolution Medicines fell sharply on Monday, losing 16.91 percent to close at $97.78 apiece, as investors unloaded portfolios following news that pharmaceutical giant Merck had cancelled ongoing negotiations for its proposed acquisition of the company. According to a report by the Wall Street Journal, Merck decided to terminate talks after failing to agree on a valuation. ...

Philip Morris International Inc. (NYSE:PM) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. Jefferies Sees Limited Re-Rating Upside for Philip Morris (PM) in 2026 On January 20, Jefferies analyst Edward Mundy moved Philip Morris International Inc. (NYSE:PM) to Hold from Buy and cut the firm’s price target to $180 from $220. In his note, he said Jefferies sees limited room for the stock to be re-rated in 2026. The analyst also pointed to tougher competition. He noted that British Amer ...

Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. Bernstein Calls 2026 a “Waiting Year” for Amgen’s (AMGN) MariTide On January 20, Bernstein downgraded Amgen Inc. (NASDAQ:AMGN) to Market Perform from Outperform, while leaving its $335 price target unchanged. The firm said the decision was mainly driven by its view that “2026 is a waiting year” for MariTide. Bernstein also flagged a few new issues that could hang over the stock, including possible risk to Repat ...

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best US stocks to buy under $50. On January 23, Cantor Fitzgerald reaffirmed its Overweight rating on Vaxcyte Inc. (NASDAQ:PCVX), keeping a positive view as the company advances its vaccine pipeline on schedule. The firm expects topline results from the Phase 3 OPUS-1 trial in late 2026, with an adult BLA filing planned for 2027. Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations It also noted pro ...